Drug Combination Details
| General Information of the Combination (ID: C26848) | |||||
|---|---|---|---|---|---|
| Name | Naringenin NP Info | + | ABT-737 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Stomach cancer
[ICD-11: 2B72]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SGC-7901 | CVCL_0520 | Human gastric cancer | Homo sapiens | ||
| Experimental
Result(s) |
ABT-737 in combination with naringenin showed enhanced anticancer effects on gastric cancer cells. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Enhanced anticancer effect of ABT-737 in combination with naringenin on gastric cancer cells. Exp Ther Med. 2016 Feb;11(2):669-673. | |||
